With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in...

[cafead]

via A panel of external experts for the FDA voted 11 to 1 in support of a narrow approval for AstraZeneca and Merck’s Lynparza, used in tandem with Johnson & Johnson’s Zytiga and a corticosteroid, in metastatic castration-resistant prostate cancer (mCRPC).

article source